Investigation of Cytotoxicity and Cell Uptake of Cationic Beta-Cyclodextrins as Valid Tools in Nasal Delivery.

cationic cyclodextrin cell uptake cyclodextrin polymer cytotoxicity epichlorohydrin cross-linker nasal delivery

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
12 Jul 2020
Historique:
received: 22 06 2020
revised: 08 07 2020
accepted: 10 07 2020
entrez: 16 7 2020
pubmed: 16 7 2020
medline: 16 7 2020
Statut: epublish

Résumé

Cyclodextrin polymers have high applicability in pharmaceutical formulations due to better biocompatibility, solubility enhancement, loading capacity and controlled drug release than their parent, cyclodextrins. The cytotoxicity and cell uptake of new cationic beta-cyclodextrin monomers and polymers were evaluated as suitable materials for nasal formulations and their protective effects on cells exposed to hydrogen peroxide were studied. PC12 and CACO-2 cells were selected as the neuronal- and epithelial-type cells, respectively, to mimic the structure of respiratory and olfactory epithelia of the nasal cavity. All cationic beta-cyclodextrin polymers tested showed dose- and time-dependent toxicity; nevertheless, at 5 µM concentration and 60 min of exposure, the quaternary-ammonium-beta-cyclodextrin soluble polymer could be recognized as nontoxic. Based on these results, a fluorescently labelled quaternary-ammonium-beta-cyclodextrin monomer and polymer were selected for uptake studies in CACO-2 cells. The monomeric and polymeric beta-cyclodextrins were internalized in the cytoplasm of CACO-2 cells; the cationic monomer showed higher permeability than the hydroxypropyl-beta-cyclodextrin, employed as comparison. Therefore, these cationic beta-cyclodextrins showed potential as excipients able to improve the nasal absorption of drugs. Furthermore, amino-beta-cyclodextrin and beta-cyclodextrin soluble polymers were able to reduce oxidative damage in PC12 and CACO-2 cells and thus could be studied as bioactive carriers or potential drugs for cell protection against oxidative stress.

Identifiants

pubmed: 32664676
pii: pharmaceutics12070658
doi: 10.3390/pharmaceutics12070658
pmc: PMC7407921
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Colloids Surf B Biointerfaces. 2014 Feb 1;114:130-7
pubmed: 24185192
J Pharm Sci. 2016 Aug;105(8):2372-80
pubmed: 27353207
Int J Pharm. 2015 Dec 30;496(2):509-17
pubmed: 26498369
J Control Release. 2015 Mar 10;201:68-77
pubmed: 25620068
Int J Pharm. 2017 Oct 15;531(2):650-657
pubmed: 28596141
Int J Pharm. 2016 Nov 30;514(1):58-72
pubmed: 27863683
Adv Drug Deliv Rev. 2006 Jul 7;58(4):467-86
pubmed: 16781003
PLoS One. 2014 Jan 08;9(1):e84856
pubmed: 24416301
Biomaterials. 2003 Mar;24(7):1121-31
pubmed: 12527253
Curr Drug Deliv. 2018;15(6):746-748
pubmed: 29065835
Molecules. 2016 May 18;21(5):
pubmed: 27213303
Pharmaceutics. 2018 Aug 03;10(3):
pubmed: 30081536
Biomolecules. 2019 Sep 20;9(10):
pubmed: 31546989
Int J Pharm. 2010 Jun 30;393(1-2):212-8
pubmed: 20394813
Biomolecules. 2019 Nov 28;9(12):
pubmed: 31795222
Int J Pharm. 2019 Jun 10;564:59-76
pubmed: 30959238
Biomacromolecules. 2009 Dec 14;10(12):3157-75
pubmed: 19921854
Beilstein J Org Chem. 2014 Dec 16;10:3007-18
pubmed: 25670971
J Drug Target. 2009 Feb;17(2):168-79
pubmed: 18985506
Pharmaceutics. 2020 Jan 17;12(1):
pubmed: 31963555
J Pharm Sci. 2016 Sep;105(9):2921-2931
pubmed: 27317368
Int J Pharm. 2018 Jan 15;535(1-2):272-284
pubmed: 29138045
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3137-42
pubmed: 22315430
Arch Med Res. 2014 Nov;45(8):711-29
pubmed: 25482528
Sci Rep. 2017 Aug 25;7(1):9481
pubmed: 28842713
J Colloid Interface Sci. 2009 Aug 15;336(2):510-8
pubmed: 19476952
Artif Cells Nanomed Biotechnol. 2018 Dec;46(8):2088-2095
pubmed: 29282995

Auteurs

Giovanna Rassu (G)

Department of Chemistry and Pharmacy, University of Sassari, via Muroni 23/a, 07100 Sassari, Italy.

Silvia Fancello (S)

Department of Medical, Surgical and Experimental Sciences, University of Sassari, viale San Pietro 43/b, 07100 Sassari, Italy.

Marta Roldo (M)

School of Pharmacy and Biomedical Sciences, University of Portsmouth, St Michael's Building, White Swan Road, Portsmouth PO1 2DT, UK.

Milo Malanga (M)

CycloLab Ltd., Illatos út 7, H-1097 Budapest, Hungary.

Lajos Szente (L)

CycloLab Ltd., Illatos út 7, H-1097 Budapest, Hungary.

Rossana Migheli (R)

Department of Medical, Surgical and Experimental Sciences, University of Sassari, viale San Pietro 43/b, 07100 Sassari, Italy.

Elisabetta Gavini (E)

Department of Chemistry and Pharmacy, University of Sassari, via Muroni 23/a, 07100 Sassari, Italy.

Paolo Giunchedi (P)

Department of Chemistry and Pharmacy, University of Sassari, via Muroni 23/a, 07100 Sassari, Italy.

Classifications MeSH